Chardan Capital Says to Buy Spark Therapeutics (ONCE) Peers Following SPK-RPE65 Results (AAVL) (VBLT)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/3/2026

1. TSLA
2. SPY
3. META
4. INTC
5. HOOD
6. STZ
7. FDS
8. FUTU
9. AMZN
10. MSFT

Go back to Chardan Capital Says to Buy Spark Therapeutics (ONCE) Peers Following SPK-RPE65 Results (AAVL) (VBLT)

Spark Therapeutics Announces Positive Top-line Results From Pivotal Phase 3 Trial of SPK-RPE65 for Genetic Blinding Conditions

October 5, 2015 6:00 AM EDT

Meets Primary and First Two Secondary Endpoints with High Statistical Significance and No Serious Adverse Events Related to SPK-RPE65

Demonstrates Restoration of Functional Vision and Improvement in Light Sensitivity in Subjects Previously Progressing toward Complete Blindness

First Randomized, Controlled Phase 3 Trial of a Gene Therapy for a Genetic Disease

PHILADELPHIA, Oct. 05, 2015 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE) today announced positive top-line results from the Phase 3 pivotal trial of its lead gene therapy product candidate, SPK-RPE65, for the... More